Ireland - English - HPRA (Health Products Regulatory Authority)

yamanouchi pharma ltd -

Israel - English - Ministry of Health

medison pharma ltd - gemcitabine as hydrochloride 200 mg/vial - powder for solution for infusion - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - English - Ministry of Health

medison pharma ltd - gemcitabine as hydrochloride 200 mg/vial - powder for solution for infusion - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - English - Ministry of Health

medison pharma ltd - gemcitabine as hydrochloride 1 g/vial - powder for solution for infusion - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - English - Ministry of Health

medison pharma ltd - gemcitabine as hydrochloride 1 g/vial - powder for solution for infusion - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

medipan, s.a. - maleato de clorfeniramina - maleato de clorfeniramina....20.00 mg / fenilefrina hidrocloruro....50.00 mg / dextrometorfano bromhidrato monohidratado....100.00 mg / acetaminofÉn....3200.00 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

medipan, s.a. - fenilefrina clorhidrato - fenilefrina clorhidrato....5 mg / clorfeniramina maleato....2 mg / acetaminofen dc 90%....325 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

medipan, s.a. - maleato de clorfeniramina - maleato de clorfeniramina....20.0 mg / fenilefrina hcl....50.0 mg / acetaminofÉn....3200.0 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

medipan, s.a - clorfeniramina maleato - clorfeniramina maleato....4.0 mg / hidrocloruro de fenilefrina....20.0 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

medipan, s.a. - fenilefrina hcl - fenilefrina hcl....5.0 mg / clorfenamina maleato....2.0 mg